Novo Nordisk shares jump about 4% after EMA panel backs Frehemgo
Novo Nordisk (NVO) shares rose about 4% after a European Medicines Agency panel recommendation for Frehemgo (denecimig), its next-generation haemophilia A treatment.
Shares of Novo Nordisk (NVO) rose about 4% on Thursday, erasing some recent declines after investors reacted to two updates on Frehemgo (denecimig), the company’s next-generation treatment for haemophilia A. The move came after a European Medicines Agency panel recommendation and newly published tr...